Your browser doesn't support javascript.
loading
Organ-Specific Toxicities Due to Radiation Therapy in Cancer Patients With or Without HIV Infection: A Systematic Review of the Literature.
Xu, Melody J; Liewen, Alison; Valle, Luca; Olson, Adam C; Zetola, Nicola M; Grover, Surbhi.
Afiliación
  • Xu MJ; Department of Radiation Oncology, University of California, San Francisco, San Francisco, CA, United States.
  • Liewen A; Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, United States.
  • Valle L; Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA, United States.
  • Olson AC; Department of Radiation Oncology, Duke University Medical Center, Durham, NC, United States.
  • Zetola NM; Hubert Yeargan Center for Global Health, Duke University, Durham, NC, United States.
  • Grover S; Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, United States.
Front Oncol ; 8: 276, 2018.
Article en En | MEDLINE | ID: mdl-30105217
Background: To synthesize published literature on the association between human immunodeficiency virus (HIV) infection and radiation therapy (RT)-related toxicities. Methods: Two electronic databases, MEDLINE and Embase, were searched to identify studies published before November 2016 comparing RT-related toxicities between HIV-infected and HIV-uninfected patients receiving RT or chemoradiation therapy (CRT) for cancer. A qualitative synthesis of included articles and organ-specific toxicities was then performed. Results: Of the 21 studies included in this review, 15 reported on anal cancer treatment, three on cervical cancer, two on Kaposi sarcoma, and one on prostate cancer. Reports in the pre-antiretroviral therapy (ART) or early ART era tended to identify increased morbidity and mortality with HIV infection. However, modern series incorporating more concurrent chemotherapy, conformal RT techniques, and ART administration result in fewer studies reporting toxicity differences in patients treated for anal and cervical cancers. When statistically significant, HIV-infected patients had higher rates of gastrointestinal toxicity with anal cancer CRT (up to 50%) and higher rates of hematologic toxicity with cervical cancer CRT (up to 31%). Of the 17 studies reporting treatment outcomes, nine suggest HIV-infected patients may have reduced local control and/or survival rates. Conclusions: Overall, RT is likely similarly tolerated between HIV-infected and HIV-uninfected patients, especially with modern RT techniques. HIV-infected patients should continue to receive established standard of care RT and CRT dosing.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Qualitative_research / Systematic_reviews Idioma: En Revista: Front Oncol Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Qualitative_research / Systematic_reviews Idioma: En Revista: Front Oncol Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos